{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:21:03Z","timestamp":1791562863984,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.ajkd.2020.09.009","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T04:00:41Z","timestamp":1603944041000},"page":"481-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial"],"prefix":"10.1053","volume":"77","author":[{"given":"Austin G.","family":"Stack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalina","family":"Dronamraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Erlandsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.ajkd.2020.09.009_bib1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10053","key":"10.1053\/j.ajkd.2020.09.009_bib2","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"issue":"1 suppl 1","key":"10.1053\/j.ajkd.2020.09.009_bib3","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"10.1053\/j.ajkd.2020.09.009_bib4","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1113\/jphysiol.2014.272328","article-title":"Diabetic kidney disease: from physiology to therapeutics","volume":"592","author":"Mora-Fernandez","year":"2014","journal-title":"J\u00a0Physiol"},{"issue":"2","key":"10.1053\/j.ajkd.2020.09.009_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.09.009_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2020.09.009_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061450","article-title":"Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in Taiwan","volume":"8","author":"Chang","year":"2013","journal-title":"PloS One"},{"issue":"11","key":"10.1053\/j.ajkd.2020.09.009_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187550","article-title":"Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis","volume":"12","author":"Su","year":"2017","journal-title":"PloS One"},{"issue":"8","key":"10.1053\/j.ajkd.2020.09.009_bib9","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2020.09.009_bib10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2020.09.009_bib11","first-page":"487","article-title":"Physiological functions and pathogenic potential of uric acid: a review","volume":"8","author":"El Ridi","year":"2017","journal-title":"J\u00a0Adv Res"},{"issue":"9","key":"10.1053\/j.ajkd.2020.09.009_bib12","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2020.09.009_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000484274","article-title":"The pathophysiology of uric acid on renal diseases","volume":"192","author":"Sanchez-Lozada","year":"2018","journal-title":"Contrib Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.09.009_bib14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41598-017-00706-7","article-title":"Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2020.09.009_bib15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: findings from two phase II trials","volume":"29","author":"Fitz-Patrick","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1053\/j.ajkd.2020.09.009_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/VHRM.S115080","article-title":"An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia","volume":"13","author":"Bove","year":"2017","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.1053\/j.ajkd.2020.09.009_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cpdd.463","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of concomitant administration of verinurad and febuxostat in healthy male volunteers","volume":"8","author":"Hall","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1053\/j.ajkd.2020.09.009_bib18","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"issue":"9","key":"10.1053\/j.ajkd.2020.09.009_bib19","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","article-title":"Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study","volume":"57","author":"Shiramoto","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1053\/j.ajkd.2020.09.009_bib20","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1053\/j.ajkd.2020.09.009_bib21","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1053\/j.ajkd.2020.09.009_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.ajkd.2020.09.009_bib23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2147\/DDDT.S140658","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects","volume":"11","author":"Shen","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2020.09.009_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1759720X16682010","article-title":"Use of febuxostat in the management of gout in the United Kingdom","volume":"9","author":"Waller","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2020.09.009_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","article-title":"Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney","volume":"18","author":"Miner","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1053\/j.ajkd.2020.09.009_bib26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2020.09.009_bib27","unstructured":"Badve SV, Tiku A, Pascoe E, et\u00a0al. Effect of allopurinol on the progression of CKD: the CKD-FIX Study. ASN Kidney Week 2019. Washington, DC; November 7-10, 2019."},{"key":"10.1053\/j.ajkd.2020.09.009_bib28","unstructured":"Doria A, Galecki A, Spino C, Mauer M. Preventing Early Renal Loss in Diabetes (PERL) Study: outcome of a 3-year trial of serum uric acid reduction with allopurinol. ASN Kidney Week 2019. Washington, DC;\u00a0November 7-10, 2019."},{"issue":"8","key":"10.1053\/j.ajkd.2020.09.009_bib29","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","article-title":"Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1053\/j.ajkd.2020.09.009_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","article-title":"The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD","volume":"15","author":"Sato","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.09.009_bib31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ki.2014.128","article-title":"Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes","volume":"87","author":"Molitch","year":"2015","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2020.09.009_bib32","first-page":"13","article-title":"Proteinuria and its relation to cardiovascular disease","volume":"7","author":"Currie","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2020.09.009_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3904\/kjim.2016.174","article-title":"New therapeutic agents in diabetic nephropathy","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J Intern Med"},{"issue":"15","key":"10.1053\/j.ajkd.2020.09.009_bib34","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"issue":"23","key":"10.1053\/j.ajkd.2020.09.009_bib35","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620310726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620310726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:31:44Z","timestamp":1759462304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638620310726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0272638620310726"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.09.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739009561.793584661","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}